Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity

Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text

Medicine, Ophthalmology, Surgery +12

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

David M. Brown, Peter K. Kaiser, Mark Michels et al. · New England Journal of Medicine · 2006 · 3.5K citations

Medicine, Ophthalmology, Pharmacotherapy +13

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

Carl D. Regillo, David M. Brown, Prema Abraham et al. · American Journal of Ophthalmology · 2008 · 862 citations

Medicine, Ophthalmology, Surgery +10

A Value-Based Medicine Analysis of Ranibizumab for the Treatment of Subfoveal Neovascular Macular Degeneration

Melissa M. Brown, Gary C. Brown, Heidi Brown et al. · Ophthalmology · 2007 · 83 citations

Medicine, Ophthalmology, Pharmacotherapy +9

Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss

Luís Arias, Félix Armadá, J. Donate-López et al. · Eye · 2008 · 67 citations

Medicine, Geriatric Medicine, Ophthalmology +13